Why the study?
Neuroleptic malignant syndrome is a potentially fatal complication of neuroleptic therapy with variable presentation, and dantrolene has emerged as a potential off-label treatment requiring prompt initiation.
Dantrolene may be utilized as an emergent off-label treatment for neuroleptic malignant syndrome.
Answers are grounded in this paper and cite their sources.
Prompt recognition of NMS may be lifesaving in the ED; Level 5 reports leave dantrolene's role open.
Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication resulting from neuroleptic drug therapy. Presentation of NMS can vary, and diagnosis relies primarily upon medical history and symptomatology. Due to the potential delay in diagnosis, emergency physicians should remain vigilant in recognizing the symptoms of NMS and be prepared to initiate immediate treatment following diagnosis. Dantrolene, which has been used for spasticity and malignant hyperthermia, has been reported as a potential treatment for NMS and led to off-label use for NMS. We report two cases of NMS induced by antipsychotic monotherapy for which dantrolene was administered.
No takes yet. Share an insight, caveat, or question.
Ngo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: